Institut für Humangenetik
Refine
Has Fulltext
- yes (123)
Is part of the Bibliography
- yes (123)
Year of publication
Document Type
- Journal article (123) (remove)
Language
- English (123) (remove)
Keywords
- DNA methylation (9)
- BRCA1 (5)
- breast cancer (5)
- heterochromatin (5)
- ovarian cancer (5)
- Anura (4)
- consortium (4)
- gene (4)
- genetics (4)
- mutations (4)
Institute
- Institut für Humangenetik (123)
- Theodor-Boveri-Institut für Biowissenschaften (19)
- Kinderklinik und Poliklinik (6)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (5)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (5)
- Medizinische Klinik und Poliklinik I (5)
- Neurologische Klinik und Poliklinik (4)
- Lehrstuhl für Orthopädie (3)
- Institut für Anatomie und Zellbiologie (2)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
Sonstige beteiligte Institutionen
- Comprehensive Hearing Center, Department of ORL, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Würzburg, Germany (1)
- DNA Analytics Core Facility, Biocenter, University of Würzburg, Würzburg, Germany (1)
- Department of Animal Ecology and Tropical Biology, University of Würzburg, Würzburg, Germany (1)
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.